Thursday, 15 October 2026European Markets

XILAM ANIMATION Stock 9.5% Up Today

Loading stream...

(vianews) - the market ended the session with xilam animation (xil.pa) jumping 9.5% to €24.20 on monday, after five consecutive sessions in a row of losses. cac 40 rose 0.52% to €7,250.35, following the last session's downward trend on what was a somewhat positive trend exchanging session today.

about xilam animation

xilam animation operates as an audiovisual production company in france and internationally. the company creates, produces, and distributes original programs for children and adults. it also broadcasts content on television; subscription video on demand streaming platforms, including netflix, disney +, amazon, and nbc universal; and advertising video on demand streaming platforms, such as youtube, facebook, rakuten tv, tubi, and pluto tv. in addition, the company produces animated, short, and feature films. it owns the oggy, cockroaches, zig & sharko, chicky, oggy oggy, oggy next gen, les contes de lupin, moka, mr magoo, trico, and j'ai perdu mon corps brands. the company was incorporated in 1999 and is headquartered in paris, france.

earnings per share

as for profitability, xilam animation has a trailing twelve months eps of €0.3.

pe ratio

xilam animation has a trailing twelve months price to earnings ratio of 80.67. meaning, the purchaser of the share is investing €80.67 for every euro of annual earnings.

more news about xilam animation (xil.pa).

In this story · Knowledge Files

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com